TABLE 4

Effects of opioids on intracranial self-stimulation

Drug PharmacologyaDosesRouteStrain/SpeciesSexICSS ProcedurebDrug EffectcDependent MeasureReference
Drug NameSelectivityStructureParameter
mg/kg
MorphineMu5.25–10.25s.c.Rat/maleMaleFree operantDepression↓rateOlds and Travis, 1960
MorphineMu10s.c.Albino ratFree operantMixed; tolerance↑↓rateAdams et al., 1972
MorphineMu5.0–20s.c.Sprague-Dawley ratMaleFree operantMixed; tolerance↑↓rateLorens and Mitchell, 1973
MorphineMu4.0–12s.c.CDF ratMaleDiscrete trialAmplitudeFacilitation↓CITMarcus and Kornetsky, 1974
MorphineMu1.0–14s.c.CDF ratMaleDiscrete trialAmplitudeMixed; tolerance↓↑CITEsposito and Kornetsky, 1977
MorphineMu1.0–18s.c.Sprague-Dawley ratMaleHybridFrequencyMixed; tolerance↑↓rateAltarifi and Negus, 2011
MorphineMu1.0–10s.c.Sprague-Dawley ratMaleHybridFrequencyMixed; tolerance↑↓rateAltarifi et al., 2012
MorphineMu2.5i.p.Long Evans ratMaleHybridFrequencyFacilitation↓θ0Carlezon and Wise, 1993a
MorphineMu1.0–5.6s.c.C57BL/6J mouseMaleHybridFrequencyFacilitation↓M50Elmer et al., 2010
MorphineMu1.0–5.6s.c.DBA mouseMaleHybridFrequencyDepression↑M50Elmer et al., 2010
HeroinMu5.0i.p.Wistar ratMaleFree operantMixed; toleranceKoob et al., 1975
MethadoneMu0.1–5.6s.c.Sprague-Dawley ratMaleHybridFrequencyMixed; tolerance↑↓rateAltarifi et al., 2012
MethadoneMu0.32–3.2s.c.Sprague-Dawley ratMaleHybridFrequencyMixed; tolerance↑↓rateAltarifi et al., 2013
FentanylMu0.001–0.1s.c.Sprague-Dawley ratMaleHybridFrequencyMixed↑↓rateAltarifi et al., 2012
FentanylMu0.001–0.1s.c.Sprague-Dawley ratMaleHybridFrequencyMixed; tolerance↑↓rateAltarifi et al., 2013
HydrocodoneMu0.1–10s.c.Sprague-Dawley ratMaleHybridFrequencyMixed↑↓rateAltarifi et al., 2012
BuprenorphineMu0.001–0.1s.c.Sprague-Dawley ratMaleHybridFrequencyFacilitation↑rateAltarifi et al., 2012
NalbuphineMu0.1–10s.c.Sprague-Dawley ratMaleHybridFrequencyFacilitation↑rateAltarifi et al., 2012
NalbuphineMu0.1–10s.c.Sprague-Dawley ratMaleHybridFrequencyMixed; tolerance↑↓rateAltarifi et al., 2013
β-FunaltrexamineMu0.32–3.2s.c.Sprague-Dawley ratMaleHybridFrequencyNo effectAltarifi et al., 2012
NaloxoneMu0.1s.c.Sprague-Dawley ratMaleHybridFrequencyNo effectAltarifi et al., 2012
NaloxoneMu20i.p.Wistar ratMaleHybridAmplitudeNo effectθ5Borowski and Kokkinidis, 1992
U-69593Kappa0.0625–0.5i.p.Sprague-Dawley ratMaleHybridFrequencyDepression↑θ0Todtenkopf et al., 2004
U-69593Kappa0.1–0.56i.p.Sprague-Dawley ratMaleHybridFrequencyDepression↑EF50Do Carmo et al., 2009
U-69593Kappa0.056–0.56i.p.Sprague-Dawley ratMaleHybridFrequencyDepression↓rateNegus et al., 2010
U-69593Kappa0.56i.p.Sprague-Dawley ratMaleHybridFrequencyDepression↓rateLeitl et al., 2014
Salvinorin AKappa0.32–3.2i.p.Sprague-Dawley ratMaleHybridFrequencyDepression↓rateNegus et al., 2012a
Salvinorin AKappa0.125–2.0i.p.Sprague-Dawley ratMaleHybridFrequencyDepression↑θ0Carlezon et al., 2006
SNC80Delta10–56i.p.Sprague-Dawley ratMaleHybridFrequencyDepression↓rateDo Carmo et al., 2009
SNC80Delta10i.p.Sprague-Dawley ratMaleHybridFrequencyDepression; tolerance↓rateNegus et al., 2012b
  • Rate, response rate; CIT, current-intensity threshold; θ0, theta-0 threshold; θ5, amplitude maintaining five responses per minute; M50 or EF50, frequency maintaining 50% maximum rate.

  • a Opioid receptor subtype selectivity.

  • b First column indicates structure of experimental session (see text for details). Second column indicates stimulation parameter under manipulation across trials.

  • c Most prominent drug effect on ICSS. Tolerance: tolerance to drug-induced depression of ICSS.